Quality of life: an important element of treatment value

Affiliations

¹ Department of Oncology, University of Turin, Division of Medical Oncology, Ordine Mauriziano Hospital, Turin 10128, Italy. Electronic address: massimo.dimaio@unito.it.

Free article

Comment

Massimo Di Maio. Lancet Oncol. 2017 Dec.

Free article

. 2017 Dec;18(12):1557-1558.

doi: 10.1016/S1470-2045(17)30697-6. Epub 2017 Nov 9.

¹ Department of Oncology, University of Turin, Division of Medical Oncology, Ordine Mauriziano Hospital, Turin 10128, Italy. Electronic address: massimo.dimaio@unito.it.

No abstract available

Comment on

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M. Brahmer JR, et al. Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9. Lancet Oncol. 2017. PMID: 29129441 Clinical Trial.